Takeda Launches New Subsidiary in Israel

Takeda Launches New Subsidiary in IsraelTakeda Launches New Subsidiary in Israel PR Newswire ZURICH, Switzerland, December 18, 2013 Demonstrates Takeda's commitment to bring new, innovative treatments to patients Takeda Pharmaceuticals International GmbH ("Takeda") today announced further expansion of its commercial platform with the establishment of its wholly-owned subsidiary in Israel. Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth sales entity Takeda has opened this year to reinforce its platform in growth markets. Takeda Israel LTD will be headquartered in the Tel Aviv area and will be responsible for the sales and marketing of selected products from Takeda's portfolio and pipeline, with an initial focus on oncology. Takeda Israel will also seek local partners with complementary portfolios, through which to launch additional proven medicines from its current portfolio. Through its established network of local partners, Takeda products currently sold in Israel are Actos® (pioglitazone), Atacand® (candesartan), Contoloc® (pantoprazole), Lucrin® (leuroprelin), Xefo® (lornoxicam), Mepact® (mifamurtide) and other treatments in various therapeutic areas. Israel is a highly developed pharma market with a universal healthcare system that values innovative medicines.